 | |
| Clinical data | |
|---|---|
| Trade names | Lenabasum |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Minimal |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C25H36O4 |
| Molar mass | 400.559 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Lenabasum (also known asajulemic acid,1',1'-dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid,DMH-D8-THC-11-OIC,AB-III-56,HU-239,IP-751,CPL 7075,CT-3,JBT-101,Anabasum, andResunab) is asyntheticcannabinoid that showsanti-fibrotic andanti-inflammatory effects inpre-clinical studies without causing a subjective "high".[1] Although its design was inspired by ametabolite ofdelta-9-THC known asdelta-9-THC-11-oic acid, lenabasum is ananalog of thedelta-8-THC metabolite delta-8-THC-11-oic acid.[2][3] It is beingdeveloped for the treatment of inflammatory and fibrotic conditions such as systemic sclerosis, dermatomyositis and cystic fibrosis.[4] It does not share theanti-emetic effects of some other cannabinoids, but may be useful for treating chronic inflammatory conditions where inflammation fails to resolve.[5] Side effects include dry mouth, tiredness, and dizziness. The mechanism of action is through activation of theCB2 receptor leading to production of specialized proresolving eicosanoids such aslipoxin A4 andprostaglandin J2. Studies in animals at doses up to 40 mg/kg show minimal psychoactivity of lenabasum, compared to that produced bytetrahydrocannabinol.[6] Lenabasum is being developed by Corbus Pharmaceuticals (formerly JB Therapeutics) for the treatment of orphan chronic life-threatening inflammatory diseases.[7] Development since been discontinued.[8]
